MicroRNA- 221可调控FAS诱导的暴发性肝功能衰竭
2011-03-07
来源:医脉通
文献标题:MicroRNA-221 regulates FAS-induced fulminant liver failure
文献出处:Hepatology. 2011 Feb 23.
期刊影响因子:10.84
研究表明:死亡受体介导的肝细胞凋亡可导致肝炎和暴发性肝功能衰竭。该论文已提前发表在《Hepatology》网络版上。
死亡受体介导的肝细胞凋亡可导致肝炎和暴发性肝功能衰竭。microRNAs(miRNAs)(19-25个核苷酸长度的非编码RNA)参与了各种凋亡路径的转录后调控。
研究人员在此报告了肝细胞中miRNA的整体丢失导致了FAS/CD95受体诱导细胞凋亡模型中细胞死亡的增加。小鼠肝脏的miRNA表达谱确定了11个保守的miRNA,后者在应答FAS诱导的暴发性肝衰竭时被上调。研究人员发现,miR- 221(一种在应答细胞凋亡时被高度上调的miRNA之一)的异位表达可保护原代肝细胞和肝癌细胞免于凋亡。重要的是,腺伴随病毒血清8型(AAV8)引起的miR- 221过表达延缓了FAS诱导的小鼠暴发性肝功能衰竭的发生。另外,研究人员还证明miR- 221可调控 Puma的肝脏表达(一种众所周知的凋亡前的Bcl2蛋白家族成员)。最后,该研究确定了miR -221是FAS诱导细胞凋亡的一个有力的转录后调节因子。并认为miR -221可作为治疗肝炎和肝功能衰竭的一个潜在靶点。
医脉通提供英文摘要
Hepatology. 2011 Feb 23. | DOI: 10.1002/hep.24243
MicroRNA-221 regulates FAS-induced fulminant liver failure
Amar Deep Sharma, Nidhi Narain, Eva-Maria Hände, Marcus Iken, Nishant Singha, Toni Cathomen, Michael Manns, Hans R. Schöler, Michael Ott, Tobias Cantz
Death receptor mediated apoptosis of hepatocytes contributes to hepatitis and fulminant liver failure. microRNAs (miRNAs), 19-25 nucleotide-long noncoding RNAs, have been implicated in the post-transcriptional regulation of the various apoptotic pathways. Here we report that global loss of miRNAs in hepatic cells leads to increased cell death in a model of FAS/CD95 receptor induced apoptosis. miRNA profiling of murine liver identified 11 conserved miRNAs, which were upregulated in response to FAS induced fulminant liver failure. We show that ectopic expression of miR-221, one of the highly upregulated miRNAs in response to apoptosis, protects primary hepatocytes and hepatoma cells from apoptosis. Importantly, in vivo overexpression of miR-221 by adeno-associated virus serotype 8 (AAV8) delays FAS induced fulminant liver failure in mice. We additionally demonstrate that miR-221 regulates hepatic expression of Puma, a well-known pro-apoptotic member of the Bcl2 protein family. In conclusion, we identified miR-221 as a potent post-transcriptional regulator of FAS induced apoptosis. miR-221 may serve as a potential therapeutic target for the treatment of hepatitis and liver failure.
(本网站所有内容,凡注明来源为“医脉通”,版权均归医脉通所有,未经授权,任何媒体、网站或个人不得转载,否则将追究法律责任,授权转载时须注明“来源:医脉通”。本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们。)